SPECIAL COMMENTARYRole of bacteriophage therapy for resistant infections in transplant recipientsNicholls, Paula; Aslam, Saimab Author Information aSection of Infectious Diseases, Department of Medicine, Baylor College of Medicine, Houston, Texas bDivision of Infectious Diseases and Global Public Health, University of California, San Diego, California, USA Correspondence to Saima Aslam, MD, MS, 4510 Executive Drive, MC 7745, San Diego, CA 92121, USA. E-mail: [email protected] Current Opinion in Organ Transplantation: December 2022 - Volume 27 - Issue 6 - p 546-553 doi: 10.1097/MOT.0000000000001029 Buy Metrics Abstract Purpose of review Multidrug-resistant organisms (MDROs) are prevalent in transplant recipients and associated with poor outcomes. We review recent cases of phage therapy used to treat recalcitrant infections in transplant recipients and explore the future role of such therapy in this setting. Recent findings Individual case reports and small case series suggest possible efficacy of phage therapy for the treatment of MDRO infections in pre and posttransplant patients. Importantly, there have been no serious safety concerns in the reported cases that we reviewed. There are no applicable randomized controlled trials (RCTs) to better guide phage therapy at this time. Summary Given the safety and possibility of successful salvage therapy of MDRO infections using bacteriophages, it is reasonable to pursue phage therapy for difficult-to-treat infections on a compassionate use basis, but RCT data are critically needed to better inform management. Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.